Department of Orthopaedics, Qilu Hospital, Shandong University Centre for Orthopaedics, Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Department of Cell Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Autophagy. 2024 Sep;20(9):2000-2016. doi: 10.1080/15548627.2024.2353548. Epub 2024 May 18.
Bleomycin exhibits effective chemotherapeutic activity against multiple types of tumors, and also induces various side effects, such as pulmonary fibrosis and neuronal defects, which limit the clinical application of this drug. Macroautophagy/autophagy has been recently reported to be involved in the functions of bleomycin, and yet the mechanisms of their crosstalk remain insufficiently understood. Here, we demonstrated that reactive oxygen species (ROS) produced during bleomycin activation hampered autophagy flux by inducing lysosomal membrane permeabilization (LMP) and obstructing lysosomal degradation. Exhaustion of ROS with N-acetylcysteine relieved LMP and autophagy defects. Notably, we observed that LMP and autophagy blockage preceded the emergence of cellular senescence during bleomycin treatment. In addition, promoting or inhibiting autophagy-lysosome degradation alleviated or exacerbated the phenotypes of senescence, respectively. This suggests the alternation of autophagy activity is more a regulatory mechanism than a consequence of bleomycin-induced cellular senescence. Taken together, we reveal a specific role of bleomycin-induced ROS in mediating defects of autophagic degradation and further regulating cellular senescence and . Our findings, conversely, indicate the autophagy-lysosome degradation pathway as a target for modulating the functions of bleomycin. These provide a new perspective for optimizing bleomycin as a clinically applicable chemotherapeutics devoid of severe side-effects.: AT2 cells: type II alveolar epithelial cells; ATG7: autophagy related 7; bEnd.3: mouse brain microvascular endothelial cells; BNIP3L: BCL2/adenovirus E1B interacting protein 3-like; CCL2: C-C motif chemokine ligand 2; CDKN1A: cyclin dependent kinase inhibitor 1A; CDKN2A: cyclin dependent kinase inhibitor 2A; FTH1: ferritin heavy polypeptide 1; γ-H2AX: phosphorylated H2A.X variant histone; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HUVEC: human umbilical vein endothelial cells; HT22: hippocampal neuronal cell lines; Il: interleukin; LAMP: lysosomal-associated membrane protein; LMP: lysosome membrane permeabilization; MTORC1: mechanistic target of rapamycin kinase complex 1; NAC: N-acetylcysteine; NCOA4: nuclear receptor coactivator 4; PI3K: phosphoinositide 3-kinase; ROS: reactive oxygen species; RPS6KB/S6K: ribosomal protein S6 kinase; SA-GLB1/β-gal: senescence-associated galactosidase, beta 1; SAHF: senescence-associated heterochromatic foci; SASP: senescence-associated secretory phenotype; SEC62: SEC62 homolog, preprotein translocation; SEP: superecliptic pHluorin; SQSTM1/p62: sequestosome 1; TFEB: transcription factor EB.
博来霉素对多种类型的肿瘤表现出有效的化疗活性,但也会引起各种副作用,如肺纤维化和神经元缺陷,这限制了这种药物的临床应用。最近有报道称,巨自噬/自噬参与了博来霉素的功能,但它们相互作用的机制还不够了解。在这里,我们证明了博来霉素激活过程中产生的活性氧 (ROS) 通过诱导溶酶体膜通透性 (LMP) 和阻碍溶酶体降解来抑制自噬流。用 N-乙酰半胱氨酸耗尽 ROS 可以缓解 LMP 和自噬缺陷。值得注意的是,我们观察到在博来霉素处理过程中,细胞衰老出现之前,LMP 和自噬阻断先于细胞衰老的出现。此外,促进或抑制自噬-溶酶体降解分别减轻或加剧衰老表型。这表明自噬活性的改变更像是一种调节机制,而不是博来霉素诱导的细胞衰老的结果。总的来说,我们揭示了博来霉素诱导的 ROS 在介导自噬降解缺陷和进一步调节细胞衰老中的特定作用。我们的发现相反表明自噬-溶酶体降解途径是调节博来霉素功能的靶点。这为优化博来霉素作为一种无严重副作用的临床应用化疗药物提供了新的视角。